Comprehensive information on Cervical Carcinoma, including Cervical Cancer and Carcinoma of the Cervix, for healthcare professionals. Learn about cervical neoplasm diagnosis, clinical documentation, and medical coding related to Cervical Carcinoma (C). Find resources for accurate and efficient healthcare data management.
Also known as
Malignant neoplasm of cervix uteri
Cancer originating in the cervix of the uterus.
Carcinoma in situ of cervix uteri
Early-stage cervical cancer confined to the surface layer.
Secondary malignant neoplasm of other specified sites
Cancer that has spread to the cervix from another primary site.
Personal history of malignant neoplasm
History of cervical cancer in remission or previously treated.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the cervical carcinoma in situ?
Yes
Code D06.9 Cervical carcinoma in situ
No
Is the histology squamous cell?
When to use each related code
| Description |
|---|
| Malignant tumor of the cervix. |
| Precancerous changes in the cervix. |
| Cancer that has spread to the cervix. |
Missing laterality (right, left, bilateral) can impact staging and treatment planning, leading to inaccurate reimbursement.
Unspecified histology (e.g., squamous cell vs. adenocarcinoma) affects coding accuracy and cancer registry data.
Documenting HPV status (positive/negative) is crucial for appropriate risk stratification and treatment selection.
Q: What are the most effective current cervical cancer screening guidelines for different age groups and risk factors in clinical practice?
A: Current cervical cancer screening guidelines recommend different approaches based on age and risk factors. For average-risk individuals, screening begins at age 21 with HPV testing every 5 years. Those aged 21-25 may still be screened with cytology (Pap smear) every 3 years, though HPV testing is preferred. For women aged 30-65, co-testing with both HPV and cytology every 5 years or HPV testing alone every 5 years are preferred options. Women over 65 with adequate prior screening and no history of high-grade precancerous lesions can discontinue screening. Higher risk individuals, such as those with HIV or immunosuppression, may require more frequent screening starting at a younger age and utilizing colposcopy more readily. Explore how our risk stratification tools can help optimize cervical cancer screening protocols in your practice.
Q: How do I differentiate between CIN 2 and CIN 3 in cervical cytology and biopsy results, and what are the recommended management strategies for each?
A: Differentiating between Cervical Intraepithelial Neoplasia (CIN) 2 and CIN 3 can be challenging. While cytology can suggest the presence of high-grade dysplasia, it cannot reliably distinguish between CIN 2 and 3. Histological evaluation via colposcopically-directed biopsy is necessary for definitive diagnosis. CIN 2 is characterized by moderate dysplasia occupying two-thirds of the epithelium, while CIN 3 shows severe dysplasia or carcinoma in situ involving the full thickness. Management for CIN 2 can involve expectant management with repeat cytology and HPV testing or ablative/excisional procedures depending on individual factors. CIN 3 typically requires excisional or ablative treatment to prevent progression to invasive cancer. Consider implementing our advanced diagnostic algorithms to enhance accuracy in distinguishing CIN grades and guide treatment decisions. Learn more about our resources for managing cervical dysplasia.
Patient presents with concerns regarding potential cervical carcinoma. Symptoms include abnormal vaginal bleeding, post-coital bleeding, and persistent pelvic pain. Patient reports a history of HPV infection. Physical examination reveals a visible lesion on the cervix. A Pap smear and HPV DNA test were performed, and colposcopy with biopsy is scheduled to confirm the diagnosis and determine staging if cervical cancer is present. Differential diagnoses include cervicitis, cervical polyps, and other gynecological conditions. Patient education was provided regarding cervical cancer risk factors, including human papillomavirus infection, smoking, and family history. The importance of regular cervical cancer screening with Pap smears and HPV testing was emphasized. Treatment options, including surgery, radiation therapy, chemotherapy, and targeted therapy, will be discussed upon confirmation of the diagnosis and staging. Medical coding will utilize ICD-10 codes for cervical carcinoma based on the final diagnosis and staging, including C53.X. Billing will reflect the procedures performed, such as colposcopy and biopsy, using appropriate CPT codes. Follow-up care and surveillance will be scheduled as necessary. This documentation supports the medical necessity of diagnostic testing and treatment for suspected cervical carcinoma.